Apriori Bio Appoints World-Class Vaccine, Immunology and Public Health Leaders to Board of Directors

Seth Berkley, M.D., Arup Chakraborty , Ph.

D., and Ashish Jha , M.D.

, MPH, join the Board CAMBRIDGE, Mass. , Sept. 24, 2024 /PRNewswire/ -- Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, announced today the addition of three esteemed leaders to its Board of Directors.

The new directors include Seth Berkley , M.D., former CEO of Gavi, the Vaccine Alliance, Arup Chakraborty , Ph.

D., Scientific Advisor and Academic Partner at Flagship Pioneering, and Ashish Jha , M.D.

, MPH, former White House COVID-19 Response Coordinator. They join Board Chair Lovisa Afzelius , Ph.D.

, General Partner at Flagship Pioneering and Co-Founder and CEO of Apriori, and Travis Wilson , Growth Partner at Flagship Pioneering. The Board will support Apriori's leadership team and the company as they advance OctaviaTM, Apriori's biology-informed artificial intelligence platform, for the development of vaccines to protect against current and potential viral threats. "I am pleased to welcome Seth, Arup and Ashish to Apriori's Board of Directors," said Board Chair Lovisa Afzelius , Ph.

D., General Partner at Flagship Pioneering and Co-Founder and CEO of Apriori. "When we launched Apriori, we set out to create a future where we can get ahead of viruses, instead of chasing them as they evolve.

The unparalleled wisdom and experience of Seth, Arup and Ashish will be instrumental as we pioneer transformative solutions to better prote.